Clinical trials: Intestinal Tuberculosis
Crohn Disease, Intestinal Tuberculosis
Validation of Scoring Systems for Differentiating Intestinal Tuberculosis from Crohn's Disease
Differentiating CD from intestinal tuberculosis (ITB) is difficult due to the low sensitivities of currently available diagnostic tests.
- Conditions
- Crohn Disease, Intestinal Tuberculosis, Differential Diagnosis
- Trial name
- NCT06629194
- Testing
- interferon gamma releasing assay (IGRA)
- Where
- 2 sites in Thailand
- Volunteers
- 84 people
- Sponsor
- Mahidol University
Tuberculosis
Potential Role of Microbiome in Tuberculosis
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a deadly infectious disease and major global public health problem.
- Trial name
- Micro-STOP (NCT04985994)
- Where
- 2 sites in Pakistan
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Khyber Medical University Peshawar
Crohn Disease, Intestinal Tuberculosis
MRI Differentiating Gut TB and Crohn's
It is clinically challenging to differentiate Crohn's disease from gut tuberculosis especially in regions endemic of tuberculosis infection.
- Trial name
- NCT03096379
- Testing
- Magnetic resonance imaging
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The University of Hong Kong
Intestinal Tuberculosis, Pulmonary Tuberculosis
Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease
One aims to devise a method for the screening and differentiation of intestinal tuberculosis and Crohn's Disease. Additionally, one aims to detect and survey multidrug resistant TB.
- Conditions
- Intestinal Tuberculosis, Pulmonary Tuberculosis, Crohn's Disease
- Trial name
- NCT01503099
- Where
- 2 sites in India, Norway
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Lovisenberg Diakonale Hospital
Crohn's Disease, Intestinal Tuberculosis
Development of a Prediction Model for Differential Diagnosis Between Intestinal Tuberculosis and Crohn's Disease
The aim of this study is to develop a scoring system and a prediction model for differential diagnosis between intestinal tuberculosis and Crohn's disease.
- Trial name
- NCT01392365
- Where
- South Korea
- Volunteers
- 117 people
- Sponsor
- Asan Medical Center
Inflammatory Bowel Disease, Crohn Disease
The Role of IGRA in Screening and Monitoring for TB During Anti TNF Therapy in Patients With IMID
Hong Kong is a region of intermediate TB burden, and the reactivation of latent TB in IMID patients treated with anti-TNF can be a serious problem.
- Conditions
- Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Tuberculosis
- Trial name
- IGRA (NCT02135289)
- Where
- Hong Kong
- Volunteers
- 9,160 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Intestinal Tuberculosis
A 15-year Cohort Study on Risk Factors of Mortality in Patients With Intestinal Tuberculosis
This study adopts a combined design of retrospective cohort study followed by prospective observational study, which is conducted at Beijing Chest Hospital.
- Trial name
- NCT07575061
- Testing
- Observational
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Beijing Chest Hospital, Capital Medical University
Tuberculosis
Treatment Duration for Abdominal Tuberculosis
Most of the guidelines on the treatment of tuberculosis suggest that 6 months treatment is sufficient for extrapulmonary tuberculosis except for bone tuberculosis and tubercular meningitis.
- Trial name
- RNTCP-DOTS (NCT01124929)
- Testing
- RNTCP Category I treatment for 6 months, RNTCP Category I treatment for 9months
- Where
- India
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences
Pulmonary Tuberculosis, Gastro-Intestinal Disorder
Prokinetic Effect of Selected Nutraceuticals
Anti-Tuberculosis Treatment (ATT) is one of the effective treatments of tuberculosis but the use of drugs for a long time put an adverse effect on the gut and other organs of the body.
- Trial name
- NCT06157034
- Testing
- Zingier officinale powder, Carum carvi, L powder, Mentha spicata oil
- Where
- Pakistan
- Volunteers
- 200 people
- Sponsor
- Allama Iqbal Open University Islamabad
Intestinal Helminth Infection, Filarial Infection
The Effect of Parasitic Worm Infections on the Immune Response to Tuberculosis Bacteria
This study, sponsored by the National Institutes of Health and the Tuberculosis Research Centre in Chennai, India, will examine how helminth and filarial infections affect the immune response to mycobacteria (the bacteria that…
- Trial name
- NCT00342017
- Where
- India
- Volunteers
- 5,200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Gastric Cancer
Volatiles in Breath and Headspace Analysis - Diagnostic Markers
Detection of Volatile Organic Compounds (VOC) directly from tissue by headspace analysis (skin, surgery material, other tissue) and exhaled breath is feasible using affordable user-friendly novel nano-chemo sensors that can…
- Conditions
- Tuberculosis, Gastric Cancer, Peptic Ulcer, Atrophic Gastritis
- Trial name
- Volatolome (NCT03228095)
- Testing
- VOC detection in breath and in skin headspace, Breath sampling, Upper endoscopy with biopsies
- Where
- Latvia
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Latvia
Rheumatoid Arthritis, Crohn's Disease
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)
This is an observational trial in Rheumatoid Arthritis and Crohn's Disease patients treated with Cimzia aiming to evaluate the risk and incidence of Tuberculosis.
- Trial name
- NCT01577264
- Where
- 45 sites in Russia
- Volunteers
- 199 people
- Sponsor
- UCB Pharma
Tuberculosis
Nyaditum Resae® as a Co-adjuvant During Treatment for Active Pulmonary Tuberculosis and Its Impact on the Gut Microbiota
This will be the first study to evaluate the use of Nyaditum resae® as a potential agent for reducing antibiotic-associated gut dysbiosis in patients with drug-susceptible TB, and potentially improving clinical and…
- Trial name
- NCT03851159
- Testing
- Nyaditum resae®, Mannitol
- Where
- 2 sites in South Africa
- Volunteers
- 48 people
- Sponsor
- University of Stellenbosch